Envista (NYSE:NVST – Free Report) had its price objective hoisted by Piper Sandler from $16.00 to $17.00 in a report released on Thursday morning, Benzinga reports. The brokerage currently has a neutral rating on the stock.
Several other research analysts have also recently issued reports on the company. Evercore ISI increased their price objective on Envista from $18.00 to $23.00 and gave the stock an “outperform” rating in a research report on Monday, September 23rd. Robert W. Baird lifted their price objective on Envista from $17.00 to $22.00 and gave the stock a “neutral” rating in a research report on Thursday. JPMorgan Chase & Co. lowered Envista from an “overweight” rating to a “neutral” rating and decreased their price target for the stock from $23.00 to $16.00 in a research note on Thursday, August 8th. Stifel Nicolaus lifted their price objective on Envista from $18.00 to $21.00 and gave the company a “buy” rating in a research note on Wednesday, October 23rd. Finally, Leerink Partners upgraded Envista from an “underperform” rating to a “market perform” rating and raised their target price for the company from $16.00 to $23.00 in a report on Thursday. One analyst has rated the stock with a sell rating, eleven have issued a hold rating and three have issued a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $20.71.
Read Our Latest Stock Analysis on Envista
Envista Stock Performance
Envista (NYSE:NVST – Get Free Report) last issued its quarterly earnings results on Wednesday, October 30th. The company reported $0.12 earnings per share for the quarter, topping the consensus estimate of $0.09 by $0.03. Envista had a positive return on equity of 3.59% and a negative net margin of 53.42%. The firm had revenue of $601.00 million during the quarter, compared to the consensus estimate of $590.34 million. During the same period last year, the company earned $0.43 earnings per share. The company’s revenue for the quarter was down 4.8% on a year-over-year basis. As a group, research analysts forecast that Envista will post 0.69 earnings per share for the current fiscal year.
Insider Transactions at Envista
In other news, CFO Eric D. Hammes acquired 24,532 shares of the firm’s stock in a transaction dated Monday, August 12th. The shares were bought at an average price of $16.33 per share, with a total value of $400,607.56. Following the acquisition, the chief financial officer now owns 24,532 shares of the company’s stock, valued at $400,607.56. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 1.30% of the stock is owned by insiders.
Institutional Trading of Envista
Several institutional investors have recently bought and sold shares of NVST. Mirae Asset Global Investments Co. Ltd. acquired a new stake in Envista in the 3rd quarter valued at $31,000. GAMMA Investing LLC increased its holdings in Envista by 69.8% in the third quarter. GAMMA Investing LLC now owns 1,766 shares of the company’s stock valued at $35,000 after purchasing an additional 726 shares during the last quarter. Blue Trust Inc. increased its holdings in Envista by 69.7% in the third quarter. Blue Trust Inc. now owns 1,957 shares of the company’s stock valued at $39,000 after purchasing an additional 804 shares during the last quarter. Allspring Global Investments Holdings LLC grew its stake in Envista by 50.8% in the third quarter. Allspring Global Investments Holdings LLC now owns 2,161 shares of the company’s stock valued at $43,000 after acquiring an additional 728 shares during the period. Finally, Versant Capital Management Inc grew its stake in Envista by 1,420.3% in the second quarter. Versant Capital Management Inc now owns 3,147 shares of the company’s stock valued at $52,000 after acquiring an additional 2,940 shares during the period.
About Envista
Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.
Featured Articles
- Five stocks we like better than Envista
- What is a Secondary Public Offering? What Investors Need to Know
- Meta’s Q3 Earnings Beat—Is This Dip a Golden Entry Opportunity?
- How the NYSE and NASDAQ are Different, Why That Matters to Investors
- Top Nuclear Stocks Thriving on Soaring Energy Demand
- What Is WallStreetBets and What Stocks Are They Targeting?
- Apple Earnings – When Really Good Just Isn’t Good Enough
Receive News & Ratings for Envista Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Envista and related companies with MarketBeat.com's FREE daily email newsletter.